FDA Approves Clinolipid for Parenteral Nutrition to Alleviate Shortage — Physician’s First Watch
FDA Approves Clinolipid for Parenteral Nutrition to Alleviate Shortage
By Kristin J. Kelley
The FDA has approved a new lipid injectable emulsion (Clinolipid) to provide parenteral nutrition for adults who can't eat or drink. The mixture of refined olive and soybean oils was granted a priority review in order to resolve a product shortage.
Clinolipid is indicated for adults only — its label will include a warning against using it in preterm infants. Additionally, it should not be given to patients with serious hyperlipidemia disorders or to those with egg- or soybean-protein hypersensitivities, and it should be used cautiously in patients with liver disease or liver insufficiency. Side effects include abnormal liver function tests, elevated blood lipid levels, high blood sugar, nausea, and vomiting.